Mesuximide

Mesuximide

Mesuximide
Systematic (IUPAC) name
(RS)-1,3-dimethyl-3-phenyl-pyrrolidine-2,5-dione
Clinical data
AHFS/Drugs.com
MedlinePlus
Pregnancy cat.
Legal status
Routes Oral
Pharmacokinetic data
Metabolism Hepatic (demethylation and glucuronidation)
Half-life 1.4–2.6 hours (mesuximide)
28–38 hours (active metabolite)
Excretion Renal
Identifiers
CAS number  YesY
ATC code N03
PubChem
DrugBank
ChemSpider  YesY
UNII  YesY
KEGG  YesY
ChEMBL  YesY
Chemical data
Formula C12H13NO2 
Mol. mass 203.237 g/mol
 N   

Mesuximide (or methsuximide, methosuximide) is a succinimide anticonvulsant medication. It is sold as a racemate by Pfizer under the tradenames Petinutin (Switzerland)[1] and Celontin (United States).[2] The therapeutic efficacy of methosuximide is largely due to its pharmacologically active metabolite, N-desmethylmethosuximide, which has a longer half-life and attains much higher plasma levels than its parent.[3]

References

  1. ^ Pfizer AG (2005). "Petinutin (Mésuximide)". Official Pfizer AG Website (in French). Retrieved August 21, 2006. 
  2. ^ Pfizer Inc. (2008). "Celontin (methsuximide capsules, USP)". Official Pfizer Inc. Website. Retrieved November 21, 2014. 
  3. ^ Porter RJ, Penry JK, Lacy JR, Newmark ME, Kupferberg HJ. Plasma concentrations of phensuximide, methosuximide, and their metabolites in relation to clinical efficacy. Neurology 29: 1509-1513, 1979.